The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,435.00
Bid: 1,454.00
Ask: 1,456.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.138%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,435.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Declaration

3 Feb 2017 13:30

RNS Number : 0142W
Indivior PLC
03 February 2017
 

Indivior PLC (the 'Company') - Director Declaration

The Board of Indivior PLC announces that Cary Claiborne has stepped down from his role as Chief Financial Officer in order to pursue other opportunities. The Board of Indivior PLC has appointed Mark Crossley to succeed Cary as CFO.

Mark is currently Chief Strategy Officer of Indivior and was previously Finance Director of the Reckitt Benckiser Pharmaceuticals division prior to the demerger.

Cary will assist with the transition over the coming weeks ahead of the scheduled release of Full Year Results on February 22. As part of the transition, we expect that Cary will step down from the Board and will be replaced by Mark in due course.

Shaun Thaxter, Chief Executive Officer of Indivior PLC, paid tribute to Cary's contribution to the Company during his tenure as Chief Financial Officer from 2014-2017:

"Cary joined us to bring public company experience to the demerger process and the establishment of Indivior as a separate, independent, listed company. He has managed through the complexities of the demerger and separation from Reckitt Benckiser, and the set-up of Indivior, including establishing corporate reporting, internal audit, tax, treasury and external audit; he has also overseen the global implementation of SAP. Throughout these many changes, the Company has delivered strong financial performance and provided transparency to our shareholders. We thank Cary for his many contributions to the successful evolution of Indivior so far and wish him well for the next phase of his career."

Mark was appointed to his current position as Chief Strategy Officer in October 2014. He joined the Company in 2012 as the Global Finance Director with responsibilities for Finance, Information Systems and Procurement. Prior to joining Indivior, Mark spent 13 years at Procter & Gamble in various finance leadership roles including Corporate Portfolio, Strategic and Business Planning (Female Beauty), as well as multiple roles in Corporate Treasury and its Baby Care division. He also enjoyed an eight year career with various operational and staff assignments in the United States Coast Guard. Mark graduated from the United States Coast Guard Academy with a BS in Management and Economics, and from Boston College with an MBA. He is a National Association of Corporate Directors Leadership Fellow.

Thaxter continued, "We welcome Mark Crossley to the role of Chief Financial Officer and look forward to benefiting from his experience and knowledge of the business in leading the finance function into the next phase of Indivior's development."

The Company confirms there is no further information to be disclosed pursuant to LR 9.6.13 in connection with Mark Crossley's appointment.

 

Media Contacts

Tulchan Communications

+44 207 353 4200

Stephen Malthouse

Jonathan Sibun

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCOKNDKNBKDCBK
Date   Source Headline
14th Mar 20244:06 pmRNSDirector/PDMR Shareholding
14th Mar 20247:00 amRNSTransaction in Own Shares
13th Mar 20242:00 pmRNSDirector/PDMR Shareholding
13th Mar 20241:09 pmRNSAnnual Financial Report
13th Mar 20247:00 amRNSTransaction in Own Shares
12th Mar 20243:33 pmRNSHolding(s) in Company
12th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 20247:00 amRNSDirector/PDMR Shareholding
11th Mar 20247:00 amRNSTransaction in Own Shares
8th Mar 20245:01 pmRNSDirector/PDMR Shareholding
8th Mar 20247:00 amRNSTransaction in Own Shares
7th Mar 20247:00 amRNSIndivior PLC Files 2023 Annual Report on Form 20-F
7th Mar 20247:00 amRNSTransaction in Own Shares
6th Mar 20245:04 pmRNSDirector/PDMR Shareholding
6th Mar 20244:59 pmRNSDirector/PDMR Shareholding
6th Mar 20244:57 pmRNSDirector/PDMR Shareholding
6th Mar 20242:30 pmRNSDirector/PDMR Shareholding
6th Mar 20247:00 amRNSTransaction in Own Shares
5th Mar 20247:00 amRNSTransaction in Own Shares
4th Mar 20242:53 pmRNSDirector/PDMR Shareholding
4th Mar 20249:35 amRNSDirector/PDMR Shareholding
4th Mar 20247:00 amRNSTransaction in Own Shares
1st Mar 20249:27 amRNSTotal Voting Rights
1st Mar 20247:00 amRNSTransaction in Own Shares
29th Feb 20247:00 amRNSTransaction in Own Shares
29th Feb 20247:00 amRNSFinal Court Approval Concludes Antitrust MDL
27th Feb 20241:32 pmRNSHolding(s) in Company
22nd Feb 20247:00 amRNSFinal Results
22nd Feb 20247:00 amRNSTransaction in Own Shares
21st Feb 20247:00 amRNSTransaction in Own Shares
20th Feb 20247:00 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSTransaction in Own Shares
16th Feb 20247:00 amRNSTransaction in Own Shares
15th Feb 20247:00 amRNSTransaction in Own Shares
14th Feb 20247:00 amRNSTransaction in Own Shares
13th Feb 20247:00 amRNSTransaction in Own Shares
9th Feb 20247:00 amRNSTransaction in Own Shares
8th Feb 20247:00 amRNSTransaction in Own Shares
7th Feb 20247:00 amRNSTransaction in Own Shares
6th Feb 20247:00 amRNSTransaction in Own Shares
5th Feb 20247:00 amRNSTransaction in Own Shares
2nd Feb 20247:00 amRNSTransaction in Own Shares
1st Feb 20248:23 amRNSTotal Voting Rights
1st Feb 20247:00 amRNSTransaction in Own Shares
31st Jan 20247:00 amRNSTransaction in Own Shares
30th Jan 20249:35 amRNSHolding(s) in Company
30th Jan 20247:00 amRNSTransaction in Own Shares
29th Jan 20247:00 amRNSTransaction in Own Shares
26th Jan 20245:37 pmRNSHolding(s) in Company
25th Jan 20242:30 pmRNSDirector/PDMR Shareholding - Correction

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.